PHILADELPHIA, PA, UNITED STATES, January 13, 2026 /EINPresswire.com/ -- Aquelyst develops environmental and molecular ...
AI is an accelerator for Duolingo, enhancing its product and growth opportunities. Click here to read why I rate DUOL stock a ...
This is Optimizer, a weekly newsletter sent every Friday from Verge senior reviewer Victoria Song that dissects and discusses ...
Economist Ludwig von Mises famously described economics as the study of human activity in a world of limited resources and unlimited wants. Central to his thinking was the idea that individuals must ...
Tim is an Australian Senior Editor based in Germany who has been passionate about video games since he first picked up a PlayStation 1 controller to play Crash Bandicoot as a kid. He started out with ...
Note: Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA) and may carry greater risks than FDA-approved treatments. In April 2025, the U.S. Food and Drug Administration ...
Forbes contributors publish independent expert analyses and insights. Wayne Winegarden covers the economic impacts of regulatory policies The new class of GLP-1 medicines exemplifies both the ...
Does compounded Semaglutide work for weight loss? Compounded semaglutide can be an affordable alternative to brand-name weight loss injections like Ozempic and Wegovy. But it’s important to understand ...
This article reviews the safety, efficacy, and regulatory concerns related to compounded semaglutide, with a focus on how health care providers can offer guidance and education to patients.
I am writing to express my concerns regarding the increasing use of non-U.S. Food and Drug Administration (FDA)-approved minocycline gel as an adjunctive treatment for periodontitis, being ordered ...
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications. The market for drugs that treat obesity and help people lose weight is soaring.
Pharmacy compounding is one of the topics in the EU Pharma Law Package that has perhaps received less attention compared to topics such as regulatory exclusivity rights, shortages, and sustainability.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results